A slower end to FY17 for UK operations has lowered market guidance to c £9m EBIT for the year, c 12% below our previous estimate (but still c 23% above FY16) and we have adjusted our model accordingly. By the FY17 results announcement (on 6 June), we will have more visibility on run rates and order intake, and will naturally review estimates for FY18 and beyond at that time. Forward P/Es are now on single-digit multiples.
Written by
WYG |
A good year, but not as good as anticipated |
FY17 year-end update |
Industrial support services |
24 March 2017 |
Share price performance
Business description
Next events
Analysts
WYG is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||||
A slower end to FY17 for UK operations has lowered market guidance to c £9m EBIT for the year, c 12% below our previous estimate (but still c 23% above FY16) and we have adjusted our model accordingly. By the FY17 results announcement (on 6 June), we will have more visibility on run rates and order intake, and will naturally review estimates for FY18 and beyond at that time. Forward P/Es are now on single-digit multiples.
Year |
Revenue (£m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
03/15 |
130.5 |
5.7 |
8.6 |
1.0 |
11.3 |
1.0 |
03/16 |
133.5 |
7.0 |
10.6 |
1.5 |
9.2 |
1.5 |
03/17e |
152.0 |
8.5 |
11.5 |
1.8 |
8.5 |
1.8 |
03/18e |
166.0 |
11.0 |
13.6 |
2.0 |
7.2 |
2.1 |
Note: *PBT and EPS (fully diluted) are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Year-end update points to slower UK order intake
UK trading has seen a quieter than anticipated end to FY17; H217 financials will be in line with or slightly ahead of the prior year, but this represents a shortfall against earlier expectations. The UK typically has a shorter order book with a significant Q4 trading period. Management cites some programme and contract award deferrals but no stand-out sectors, contracts or customer types behind this. We should note that FY17 group PBT will still show a good y-o-y uplift driven largely by progress in most overseas operations. We had expected a return to a funds-neutral position at the year-end (versus £4.9m net debt at the H1 stage). The indicated net debt of c £6m is therefore likely to reflect a combination of lower expected profit, a less favourable working capital position (probably appearing in WiP and debtors) and some cash exceptionals (see below). We have also factored in £3m cash consideration for already announced acquisitions, of which c £2.3m relates to H2.
Reduced estimates, group changes
Following the year-end update, we have reduced our expected group revenue and EBIT (and PBT) by a net £3m and £1m (or c 2% and c 10%) respectively for FY17. In the mix, the UK adjustments are slightly higher than this, partly offset by better overseas trading. WYG is in the process of updating its business strategy and changing the group structure. Costs of c £1.7m are anticipated for this; together with some associated accelerated contract adjustments in Poland gives a total c £2.5m exceptional charge for FY17. Most of the related cash outflow will fall into FY17. At this stage, we have made no changes to our out year estimates; some of the deferred project work may come in during Q117 and the impact on run rates and order intake will be better judged with FY17 results in June.
Valuation: Rating compression follows update
A c 24% share price markdown following the year end update – well in excess of the FY17 estimate revision – resulted in rating compression. A reiteration of management confidence in the FY18 outlook backed by order backlog in June would help towards restoring dented investor sentiment.
Exhibit 1: Financial summary
£'ms |
2013 |
2014 |
2015 |
2016 |
2017e |
2018e |
2019e |
||
March |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
|
|
IAS19R |
IAS19R |
IAS19R |
IAS19R |
IAS19R |
IAS19R |
IAS19R |
Revenue |
|
|
125.7 |
126.9 |
130.5 |
133.5 |
152.0 |
166.0 |
178.5 |
EBITDA |
|
|
3.3 |
6.4 |
7.2 |
9.0 |
11.2 |
13.7 |
14.5 |
Operating Profit (before GW and except.) |
1.5 |
4.8 |
5.4 |
7.2 |
8.9 |
11.3 |
12.0 |
||
Net Interest |
|
|
(0.8) |
(0.6) |
(0.1) |
(0.2) |
(0.5) |
(0.4) |
(0.3) |
JV / Associates |
|
|
0.0 |
0.0 |
0.4 |
0.0 |
0.1 |
0.0 |
0.0 |
Intangible Amortisation |
|
|
(1.0) |
(1.2) |
(1.3) |
(1.5) |
(2.0) |
(2.0) |
(2.0) |
Other |
|
|
(2.5) |
(3.7) |
(2.9) |
(1.5) |
(1.0) |
(1.0) |
(1.0) |
Exceptionals |
|
|
(0.6) |
2.4 |
0.0 |
(1.8) |
(2.5) |
0.0 |
0.0 |
Profit Before Tax (norm) |
|
|
0.7 |
4.3 |
5.7 |
7.0 |
8.5 |
11.0 |
11.7 |
Profit Before Tax (FRS 3) |
|
|
(3.3) |
1.8 |
1.4 |
2.2 |
3.0 |
8.0 |
8.7 |
Tax |
|
|
(0.1) |
0.3 |
0.5 |
0.6 |
0.0 |
(0.9) |
(1.0) |
Minorities |
|
|
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Profit After Tax (norm) |
|
|
0.7 |
4.5 |
6.2 |
7.6 |
8.5 |
10.1 |
10.7 |
Profit After Tax (FRS 3) |
|
|
(3.4) |
2.1 |
1.9 |
2.8 |
3.0 |
7.1 |
7.7 |
|
|
|
|
|
|
|
|
|
|
Average Number of Shares Outstanding (m) |
|
64.5 |
64.6 |
65.8 |
70.6 |
68.4 |
68.4 |
68.4 |
|
EPS - normalised fully diluted (p) |
|
|
0.8 |
6.4 |
8.6 |
10.6 |
11.5 |
13.6 |
14.4 |
EPS - FRS 3 (p) |
|
|
(5.2) |
3.2 |
2.9 |
4.0 |
4.4 |
10.4 |
11.2 |
Dividend per share (p) |
|
|
0.0 |
0.5 |
1.0 |
1.5 |
1.8 |
2.0 |
2.2 |
|
|
|
|
|
|
|
|
|
|
EBITDA Margin (%) |
|
|
2.6 |
5.1 |
5.5 |
6.8 |
7.3 |
8.3 |
8.1 |
Operating Margin (before GW and except.) (%) |
1.2 |
3.8 |
4.1 |
5.4 |
5.9 |
6.8 |
6.7 |
||
|
|
|
|
|
|
|
|
|
|
BALANCE SHEET |
|
|
|
|
|
|
|
|
|
Fixed Assets |
|
|
18.6 |
19.8 |
22.0 |
32.3 |
34.4 |
33.4 |
31.2 |
Intangible Assets |
|
|
16.3 |
17.6 |
18.7 |
27.5 |
28.7 |
27.1 |
25.0 |
Tangible Assets |
|
|
2.4 |
2.2 |
2.3 |
3.2 |
3.9 |
4.5 |
4.4 |
Investments |
|
|
0.0 |
0.0 |
0.9 |
1.6 |
1.8 |
1.8 |
1.8 |
Current Assets |
|
|
66.8 |
60.0 |
54.6 |
62.5 |
65.8 |
64.4 |
74.7 |
Stocks |
|
|
20.2 |
21.6 |
21.1 |
30.4 |
32.7 |
31.4 |
32.9 |
Debtors |
|
|
23.0 |
18.5 |
18.5 |
19.7 |
22.9 |
26.0 |
28.0 |
Cash |
|
|
19.597 |
15.9 |
12.3 |
8.2 |
6.7 |
3.5 |
10.3 |
Current Liabilities |
|
|
(45.7) |
(42.9) |
(40.8) |
(50.7) |
(56.7) |
(50.7) |
(52.6) |
Creditors |
|
|
(44.8) |
(42.3) |
(40.8) |
(47.6) |
(49.2) |
(50.7) |
(52.6) |
Short term borrowings |
|
|
(0.953) |
(0.7) |
0.0 |
(3.1) |
(7.5) |
0.0 |
0.0 |
Long Term Liabilities |
|
|
(23.3) |
(16.9) |
(13.2) |
(15.8) |
(11.9) |
(9.7) |
(9.5) |
Long term borrowings |
|
|
0.0 |
0.0 |
0.0 |
(5.0) |
(5.0) |
(5.0) |
(5.0) |
Other long term liabilities |
|
|
(23.3) |
(16.9) |
(13.2) |
(10.8) |
(6.9) |
(4.7) |
(4.5) |
Net Assets |
|
|
16.4 |
20.1 |
22.5 |
28.3 |
31.6 |
37.4 |
43.7 |
|
|
|
|
|
|
|
|
|
|
CASH FLOW |
|
|
|
|
|
|
|
|
|
Operating Cash Flow |
|
|
(2.6) |
(0.1) |
2.4 |
(1.0) |
2.1 |
10.2 |
11.8 |
Net Interest |
|
|
(0.8) |
(0.5) |
(0.1) |
(0.2) |
(0.5) |
(0.4) |
(0.3) |
Tax |
|
|
(0.2) |
(0.0) |
(0.3) |
(0.3) |
(0.9) |
(0.9) |
(0.9) |
Capex |
|
|
(1.3) |
(1.4) |
(1.7) |
(2.5) |
(2.9) |
(2.9) |
(2.4) |
Acquisitions/disposals |
|
|
(0.8) |
(1.4) |
(1.6) |
(7.9) |
(3.0) |
(0.5) |
0.0 |
Financing |
|
|
(0.0) |
0.0 |
(0.2) |
0.0 |
0.0 |
0.0 |
0.0 |
Dividends |
|
|
0.0 |
0.0 |
(0.5) |
(0.8) |
(1.1) |
(1.3) |
(1.4) |
Net Cash Flow |
|
|
(5.6) |
(3.3) |
(2.0) |
(12.6) |
(6.3) |
4.3 |
6.8 |
Opening net debt/(cash) |
|
|
(23.0) |
(18.6) |
(15.2) |
(12.3) |
(0.2) |
5.8 |
1.5 |
HP finance leases initiated |
|
|
(0.0) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Other |
|
|
1.3 |
(0.2) |
(0.9) |
0.5 |
0.3 |
0.0 |
0.0 |
Closing net debt/(cash) |
|
|
(18.6) |
(15.2) |
(12.3) |
(0.2) |
5.8 |
1.5 |
(5.3) |
Source: Company accounts, Edison Investment Research
|
|
Research: Healthcare
Transgene has announced the initiation of two clinical trials of its main assets in combination with immune checkpoint inhibitors (ICIs). A Phase I trial of oncolytic virus Pexa-Vec in combination with Yervoy in solid tumours has started. Additionally, a Phase II study of the therapeutic vaccine TG4010 with Opdivo in second-line advanced lung cancer has started at UC Davis in collaboration with Bristol-Myers Squibb; initial results from both trials are expected later this year. Cash and equivalents at end 2016 amount to €56.2m. Our updated valuation is €204m or €3.6/share.